Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response

To determine the effects of tamoxifen on the levels of hormone receptors and proliferation markers in the early phase of treatment and the relationship of the changes with tumor response in patients with primary breast cancer. Twenty-one women with primary, operable breast carcinomas were treated wi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment Jg. 48; H. 1; S. 11 - 20
Hauptverfasser:	Makris, A., Powles, T.J., Allred, D.C., Ashley, S., Ormerod, M.G., Titley, J.C., Dowsett, M.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Dordrecht Springer 01.03.1998 Springer Nature B.V
Schlagworte:	Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Biomarkers, Tumor - analysis Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Cancer research Carcinoma - drug therapy Carcinoma - metabolism Chemotherapy Female Flow Cytometry Humans Immunohistochemistry Ki-67 Antigen - analysis Medical sciences Medical treatment Pharmacology. Drug treatments Receptors, Cell Surface - analysis Tamoxifen - therapeutic use Antineoplastic agent Human Cell proliferation Ploidy Carcinoma Treatment efficiency Antiestrogen Estrogen Biological marker Malignant tumor Antihormone Tamoxifene Mammary gland diseases Chemotherapy Sensitivity resistance Treatment S Phase Female Mammary gland Progesterone Non steroid compound Hormonal receptor
ISSN:	0167-6806, 1573-7217
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	To determine the effects of tamoxifen on the levels of hormone receptors and proliferation markers in the early phase of treatment and the relationship of the changes with tumor response in patients with primary breast cancer. Twenty-one women with primary, operable breast carcinomas were treated with tamoxifen 20 mg daily. Fine needle aspiration (FNA) was used to obtain samples prior to the start and at 14 days and 8-weeks post-treatment. From these samples estrogen receptor (ER), progesterone receptor (PgR), and Ki67 levels were determined using immunocytochemistry and ploidy and S-phase fraction (SPF) using flow cytometry. Tumor response was measured clinically according to UICC criteria. There were 12 responders (2 CR, 10 PR) and 9 non-responders (2 NC, 7 PD). Responders were more likely to be ER+ (p = 0.002), PgR+ (p = 0.006), and low SPF (p = 0.06). At 14 days post-tamoxifen, the median decrease in Ki67 (% cells staining) for responders was -4.8 and for non-responders -0.15 (p = 0.005). This decrease was seen predominantly in ER+ tumours. The difference in SPF was not significant. A decrease in ER was seen in 3/15 patients all of whom were responders. A rise in PgR was seen in 7/17 patients and all but one were responders. Similar changes for ER and PgR were seen at 8-weeks post-tamoxifen, although the reductions in Ki67 and SPF at that time point were not related to response. We have observed a decrease in Ki67 and ER and a rise in PgR after 14 days of treatment with tamoxifen that was related to subsequent response. This is the first study in which an early decrease in a proliferation marker has been shown to relate to subsequent clinical response.
AbstractList	Aim: To determine the effects of tamoxifen on the levels of hormone receptors and proliferation markers in the early phase of treatment and the relationship of the changes with tumor response in patients with primary breast cancer. Methods: Twenty-one women with primary, operable breast carcinomas were treated with tamoxifen 20 mg daily. Fine needle aspiration (FNA) was used to obtain samples prior to the start and at 14 days and 8-weeks post-treatment. From these samples estrogen receptor (ER), progesterone receptor (PgR), and Ki67 levels were determined using immunocytochemistry and ploidy and S-phase fraction (SPF) using flow cytometry. Tumor response was measured clinically according to UICC criteria. Results: There were 12 responders (2 CR, 10 PR) and 9 non-responders (2 NC, 7 PD). Responders were more likely to be ER + (p=0.002), PgR + (p=0.006), and low SPF (p=0.06). At 14 days post-tamoxifen, the median decrease in Ki67 (% cells staining) for responders was - 4.8 and for non-responders - 0.15 (p=0.005). This decrease was seen predominantly in ER + tumours. The difference in SPF was not significant. A decrease in ER was seen in 3/15 patients all of whom were responders. A rise in PgR was seen in 7/17 patients and all but one were responders. Similar changes for ER and PgR were seen at 8-weeks post-tamoxifen, although the reductions in Ki67 and SPF at that time point were not related to response. Conclusion: We have observed a decrease in Ki67 and ER and a rise in PgR after 14 days of treatment with tamoxifen that was related to subsequent response. This is the first study in which an early decrease in a proliferation marker has been shown to relate to subsequent clinical response.[PUBLICATION ABSTRACT] To determine the effects of tamoxifen on the levels of hormone receptors and proliferation markers in the early phase of treatment and the relationship of the changes with tumor response in patients with primary breast cancer.AIMTo determine the effects of tamoxifen on the levels of hormone receptors and proliferation markers in the early phase of treatment and the relationship of the changes with tumor response in patients with primary breast cancer.Twenty-one women with primary, operable breast carcinomas were treated with tamoxifen 20 mg daily. Fine needle aspiration (FNA) was used to obtain samples prior to the start and at 14 days and 8-weeks post-treatment. From these samples estrogen receptor (ER), progesterone receptor (PgR), and Ki67 levels were determined using immunocytochemistry and ploidy and S-phase fraction (SPF) using flow cytometry. Tumor response was measured clinically according to UICC criteria.METHODSTwenty-one women with primary, operable breast carcinomas were treated with tamoxifen 20 mg daily. Fine needle aspiration (FNA) was used to obtain samples prior to the start and at 14 days and 8-weeks post-treatment. From these samples estrogen receptor (ER), progesterone receptor (PgR), and Ki67 levels were determined using immunocytochemistry and ploidy and S-phase fraction (SPF) using flow cytometry. Tumor response was measured clinically according to UICC criteria.There were 12 responders (2 CR, 10 PR) and 9 non-responders (2 NC, 7 PD). Responders were more likely to be ER+ (p = 0.002), PgR+ (p = 0.006), and low SPF (p = 0.06). At 14 days post-tamoxifen, the median decrease in Ki67 (% cells staining) for responders was -4.8 and for non-responders -0.15 (p = 0.005). This decrease was seen predominantly in ER+ tumours. The difference in SPF was not significant. A decrease in ER was seen in 3/15 patients all of whom were responders. A rise in PgR was seen in 7/17 patients and all but one were responders. Similar changes for ER and PgR were seen at 8-weeks post-tamoxifen, although the reductions in Ki67 and SPF at that time point were not related to response.RESULTSThere were 12 responders (2 CR, 10 PR) and 9 non-responders (2 NC, 7 PD). Responders were more likely to be ER+ (p = 0.002), PgR+ (p = 0.006), and low SPF (p = 0.06). At 14 days post-tamoxifen, the median decrease in Ki67 (% cells staining) for responders was -4.8 and for non-responders -0.15 (p = 0.005). This decrease was seen predominantly in ER+ tumours. The difference in SPF was not significant. A decrease in ER was seen in 3/15 patients all of whom were responders. A rise in PgR was seen in 7/17 patients and all but one were responders. Similar changes for ER and PgR were seen at 8-weeks post-tamoxifen, although the reductions in Ki67 and SPF at that time point were not related to response.We have observed a decrease in Ki67 and ER and a rise in PgR after 14 days of treatment with tamoxifen that was related to subsequent response. This is the first study in which an early decrease in a proliferation marker has been shown to relate to subsequent clinical response.CONCLUSIONWe have observed a decrease in Ki67 and ER and a rise in PgR after 14 days of treatment with tamoxifen that was related to subsequent response. This is the first study in which an early decrease in a proliferation marker has been shown to relate to subsequent clinical response. To determine the effects of tamoxifen on the levels of hormone receptors and proliferation markers in the early phase of treatment and the relationship of the changes with tumor response in patients with primary breast cancer. Twenty-one women with primary, operable breast carcinomas were treated with tamoxifen 20 mg daily. Fine needle aspiration (FNA) was used to obtain samples prior to the start and at 14 days and 8-weeks post-treatment. From these samples estrogen receptor (ER), progesterone receptor (PgR), and Ki67 levels were determined using immunocytochemistry and ploidy and S-phase fraction (SPF) using flow cytometry. Tumor response was measured clinically according to UICC criteria. There were 12 responders (2 CR, 10 PR) and 9 non-responders (2 NC, 7 PD). Responders were more likely to be ER+ (p = 0.002), PgR+ (p = 0.006), and low SPF (p = 0.06). At 14 days post-tamoxifen, the median decrease in Ki67 (% cells staining) for responders was -4.8 and for non-responders -0.15 (p = 0.005). This decrease was seen predominantly in ER+ tumours. The difference in SPF was not significant. A decrease in ER was seen in 3/15 patients all of whom were responders. A rise in PgR was seen in 7/17 patients and all but one were responders. Similar changes for ER and PgR were seen at 8-weeks post-tamoxifen, although the reductions in Ki67 and SPF at that time point were not related to response. We have observed a decrease in Ki67 and ER and a rise in PgR after 14 days of treatment with tamoxifen that was related to subsequent response. This is the first study in which an early decrease in a proliferation marker has been shown to relate to subsequent clinical response.
Author	Allred, D.C. Ormerod, M.G. Titley, J.C. Powles, T.J. Makris, A. Ashley, S. Dowsett, M.
Author_xml	– sequence: 1 givenname: A. surname: Makris fullname: Makris, A. – sequence: 2 givenname: T.J. surname: Powles fullname: Powles, T.J. – sequence: 3 givenname: D.C. surname: Allred fullname: Allred, D.C. – sequence: 4 givenname: S. surname: Ashley fullname: Ashley, S. – sequence: 5 givenname: M.G. surname: Ormerod fullname: Ormerod, M.G. – sequence: 6 givenname: J.C. surname: Titley fullname: Titley, J.C. – sequence: 7 givenname: M. surname: Dowsett fullname: Dowsett, M.
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2169389$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9541185$$D View this record in MEDLINE/PubMed
BookMark	eNp1kUtv1TAQhS1UVG4La1ZIlkDdhXrsOI7ZXV1RqFSpm7KOXGdMXBIn2L4CfgD_G98HSFTqyo_5zhnP8Rk5CXNAQl4Dew-Mi8v1B2BMaiUk15rDM7ICqUSlOKgTsmLQqKppWfOCnKX0wBjTiulTcqplDdDKFfm9GUz4ion6QIc5TsWdRrS45DkmakJPlziP3mE02c-BTiZ-w7jHs5nmn6VSdhFNxp7elzVlak2wGOlSFBjywSUPO99xb5IGv9AfPg_lJi3ljC_Jc2fGhK-O6zn5cvXxbvO5urn9dL1Z31RW1DpXpheqkcYACgmNaJzWUnGFrG976Vhb11zqfjebQwe9MuBaY-vaibZhHIw4JxcH3zLU9y2m3E0-WRxHE3Depk5p1dbQ8AK-fQQ-zNsYytu6EruCGmoFhXpzpLb3E_bdEn3J51d3TLfU3x3rJlkzuliC8ekfxqHRotUFkwfMxjmliK6zPu-TytH4sXTcNRXduvvvr4vu8pHur_NTij_qjqtB
CODEN	BCTRD6
CitedBy_id	crossref_primary_10_1016_j_clbc_2025_04_019 crossref_primary_10_1378_chest_117_1_25 crossref_primary_10_1016_j_clbc_2014_06_005 crossref_primary_10_1016_S0140_6736_05_78743_2 crossref_primary_10_1093_annonc_mdl943 crossref_primary_10_1002_cncr_11836 crossref_primary_10_1016_S0039_128X_00_00116_1 crossref_primary_10_1097_01_pai_0000137364_36091_b0 crossref_primary_10_1200_JCO_2000_18_7_1558 crossref_primary_10_1016_j_ejso_2003_03_001 crossref_primary_10_1016_j_jsbmb_2005_04_010 crossref_primary_10_1093_jnci_95_11_779 crossref_primary_10_1016_S0960_0760_00_00101_1 crossref_primary_10_1186_bcr1508 crossref_primary_10_1111_j_1075_122X_2004_21594_x crossref_primary_10_15171_apb_2018_076 crossref_primary_10_1002_dc_21580 crossref_primary_10_3816_CBC_2005_n_034 crossref_primary_10_1016_S0959_8049_02_00530_0 crossref_primary_10_1016_S0959_8049_02_00600_7 crossref_primary_10_1016_j_ejso_2007_07_002 crossref_primary_10_3816_CBC_2003_s_013 crossref_primary_10_1054_brst_2000_0140 crossref_primary_10_1093_jnci_95_11_766 crossref_primary_10_3892_etm_2010_133 crossref_primary_10_1186_1471_2407_9_375 crossref_primary_10_1023_A_1006348907994 crossref_primary_10_1097_00006842_200207000_00011 crossref_primary_10_1111_his_14331 crossref_primary_10_1002_ijc_34430 crossref_primary_10_1200_JCO_2005_07_501 crossref_primary_10_1023_A_1008345901178 crossref_primary_10_1158_1078_0432_CCR_04_0171 crossref_primary_10_1158_1078_0432_CCR_08_0974 crossref_primary_10_1155_2014_390618 crossref_primary_10_1002_ijc_24884 crossref_primary_10_1002_ijc_27997 crossref_primary_10_2217_fon_2021_1107 crossref_primary_10_1002_cncr_20298 crossref_primary_10_1186_1477_7819_7_35 crossref_primary_10_1158_1078_0432_951s_11_2 crossref_primary_10_1111_joa_12298 crossref_primary_10_1023_B_BREA_0000003968_45511_3f crossref_primary_10_1054_brst_2002_0408 crossref_primary_10_1093_jjco_hys161 crossref_primary_10_1023_A_1006469627067 crossref_primary_10_1016_S0960_9776_16_30019_4 crossref_primary_10_1002__SICI_1097_0215_19990412_81_2_309__AID_IJC23_3_0_CO_2_S crossref_primary_10_1111_j_1365_2184_2009_00664_x crossref_primary_10_1186_bcr2931 crossref_primary_10_1007_BF02524794
Cites_doi	10.1016/S0305-7372(78)80017-6 10.1002/cyto.990150211 10.1002/cyto.990130306 10.1007/978-3-642-82188-2_23 10.1056/NEJM198902233200802 10.1001/archsurg.1990.01410130113018 10.1200/JCO.1986.4.4.459 10.1200/JCO.1992.10.8.1284 10.1093/ajcp/82.5.559 10.1016/0960-9776(92)90212-K 10.1002/1097-0142(19800815)46:4<844::AID-CNCR2820460434>3.0.CO;2-5 10.1136/bmj.284.6319.869-a 10.1016/0014-2964(80)90348-5 10.1002/ijc.2910310104 10.1038/bjc.1993.111 10.1038/bjc.1977.42 10.1016/0959-8049(94)90161-9
ContentType	Journal Article
Copyright	1998 INIST-CNRS Kluwer Academic Publishers 1998
Copyright_xml	– notice: 1998 INIST-CNRS – notice: Kluwer Academic Publishers 1998
DBID	AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 K9- K9. M0R M0S M1P M2O MBDVC PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8
DOI	10.1023/A:1005973529921
DatabaseName	CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts Consumer Health Database ProQuest Health & Medical Complete (Alumni) Consumer Health Database ProQuest Health & Medical Collection Medical Database Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Research Library Prep MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1573-7217
EndPage	20
ExternalDocumentID	2716461831 9541185 2169389 10_1023_A_1005973529921
Genre	Research Support, U.S. Gov't, P.H.S Comparative Study Research Support, Non-U.S. Gov't Journal Article
GrantInformation_xml	– fundername: NCI NIH HHS grantid: CA30195 – fundername: NCI NIH HHS grantid: P30-CA 54174
GroupedDBID	--- -XW -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 23N 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3O- 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6NX 78A 7X7 88E 8AO 8C1 8FI 8FJ 8G5 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAPKM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYXX ABAKF ABBBX ABBRH ABBXA ABDBE ABDZT ABECU ABFSG ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABRTQ ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACIHN ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSTC ACUDM ACZOJ ADBBV ADHHG ADHIR ADHKG ADIMF ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AETLH AEVLU AEXYK AEZWR AFBBN AFDYV AFDZB AFEXP AFFHD AFFNX AFHIU AFJLC AFKRA AFLOW AFOHR AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGQPQ AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHPBZ AHSBF AHWEU AHYZX AIAKS AIGIU AIIXL AILAN AITGF AIXLP AJBLW AJRNO AJZVZ AKMHD ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG ATHPR AVWKF AXYYD AYFIA AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BKNYI BPHCQ BSONS BVXVI CAG CCPQU CITATION COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ7 GQ8 GRRUI GUQSH GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO ICW IHE IHR IHW IJ- IKXTQ IMOTQ INH INR ITC ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ K9- KDC KOV KOW KPH LAK LLZTM M0R M1P M2O M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UDS UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AAYZH AESKC ALIPV IQODW -53 -5E -5G -BR -EM 3V. ADINQ CGR CUY CVF ECM EIF GQ6 NPM Z7U Z7W Z81 Z82 Z83 Z87 Z8O Z8Q Z8U Z8V Z8W Z91 7TO 7XB 8FK H94 K9. MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8
ID	FETCH-LOGICAL-c349t-ad3765aa1e351636f995727e0d8d5f0844259d9541fef1d7a1f8ac44f386021a3
IEDL.DBID	BENPR
ISICitedReferencesCount	72
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000072340000002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0167-6806
IngestDate	Sun Nov 09 10:58:00 EST 2025 Wed Nov 26 12:51:17 EST 2025 Wed Feb 19 02:35:45 EST 2025 Mon Jul 21 09:13:05 EDT 2025 Tue Nov 18 22:05:00 EST 2025 Sat Nov 29 07:50:31 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Antineoplastic agent Human Cell proliferation Ploidy Carcinoma Treatment efficiency Antiestrogen Estrogen Biological marker Malignant tumor Antihormone Tamoxifene Mammary gland diseases Chemotherapy Sensitivity resistance Treatment S Phase Female Mammary gland Progesterone Non steroid compound Hormonal receptor
Language	English
License	https://www.springernature.com/gp/researchers/text-and-data-mining CC BY 4.0
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c349t-ad3765aa1e351636f995727e0d8d5f0844259d9541fef1d7a1f8ac44f386021a3
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23
PMID	9541185
PQID	1027141471
PQPubID	36266
PageCount	10
ParticipantIDs	proquest_miscellaneous_79784162 proquest_journals_1027141471 pubmed_primary_9541185 pascalfrancis_primary_2169389 crossref_citationtrail_10_1023_A_1005973529921 crossref_primary_10_1023_A_1005973529921
PublicationCentury	1900
PublicationDate	1998-03-01
PublicationDateYYYYMMDD	1998-03-01
PublicationDate_xml	– month: 03 year: 1998 text: 1998-03-01 day: 01
PublicationDecade	1990
PublicationPlace	Dordrecht
PublicationPlace_xml	– name: Dordrecht – name: Netherlands
PublicationTitle	Breast cancer research and treatment
PublicationTitleAlternate	Breast Cancer Res Treat
PublicationYear	1998
Publisher	Springer Springer Nature B.V
Publisher_xml	– name: Springer – name: Springer Nature B.V
References	A Paradiso (149442_CR23) 1990; 50 Early Breast Cancer Trialists (149442_CR4) 1992; 339 M Schwartz (149442_CR20) 1980; 46 H Mouridsen (149442_CR1) 1978; 5 JL Hayward (149442_CR28) 1977; 35 SRD Johnston (149442_CR22) 1995; 30A M Brifford (149442_CR18) 1992; 13 149442_CR24 JN Sarkaria (149442_CR19) 1993; 53 M Dowsett (149442_CR31) 1996; 37 KI Pritchard (149442_CR14) 1987; 5 A Howell (149442_CR16) 1987; 47 FA Mauri (149442_CR33) 1994; 2 PA Murray (149442_CR35) 1994; 30A RB Clarke (149442_CR21) 1993; 67 HT Mouridsen (149442_CR13) 1986; 1 KJ Walker (149442_CR25) 1988; 48 MG Ormerod (149442_CR27) 1994 T Bates (149442_CR9) 1992; 1 J Gerdes (149442_CR32) 1983; 31 JC Allegra (149442_CR2) 1980; 16 JW Bradheer (149442_CR8) 1983; 9 PM Ravdin (149442_CR11) 1992; 10 B Fisher (149442_CR6) 1989; 320 A Makris (149442_CR29) 1996; 15 DC Allred (149442_CR26) 1990; 125 CK Osborne (149442_CR10) 1984; 44 R Silvestrini (149442_CR15) 1984; 91 B Fisher (149442_CR12) 1986; 4 M Namer (149442_CR17) 1980; 40 W Gorczyca (149442_CR30) 1994; 15 RA Saez (149442_CR3) 1989 Nolvadex Adjuvant Trial Organisation (149442_CR5) 1985; 1 E Greenbaum (149442_CR34) 1984; 32 PE Preece (149442_CR7) 1982; 284
References_xml	– volume: 5 start-page: 131 year: 1978 ident: 149442_CR1 publication-title: Cancer Treat Rev doi: 10.1016/S0305-7372(78)80017-6 – volume: 15 start-page: 169 year: 1994 ident: 149442_CR30 publication-title: Cytometry doi: 10.1002/cyto.990150211 – volume: 53 start-page: 4413 year: 1993 ident: 149442_CR19 publication-title: Cancer Research – volume: 13 start-page: 250 year: 1992 ident: 149442_CR18 publication-title: Cytometry doi: 10.1002/cyto.990130306 – volume-title: A practical approach year: 1994 ident: 149442_CR27 – volume: 50 start-page: 2958 year: 1990 ident: 149442_CR23 publication-title: Cancer Research – volume: 91 start-page: 163 year: 1984 ident: 149442_CR15 publication-title: Recent Results Cancer Res doi: 10.1007/978-3-642-82188-2_23 – volume: 44 start-page: 1433 year: 1984 ident: 149442_CR10 publication-title: Cancer Res – volume: 15 start-page: 96 year: 1996 ident: 149442_CR29 publication-title: Proc Annu Meet Am Soc Clin Oncol – volume: 320 start-page: 479 year: 1989 ident: 149442_CR6 publication-title: N Engl J Med doi: 10.1056/NEJM198902233200802 – volume: 1 start-page: 836 year: 1985 ident: 149442_CR5 publication-title: Lancet – volume: 9 start-page: 31 year: 1983 ident: 149442_CR8 publication-title: Clin Oncol – start-page: 163 volume-title: Current Clinical Oncology year: 1989 ident: 149442_CR3 – volume: 2 start-page: 171 year: 1994 ident: 149442_CR33 publication-title: Appl Immunohistochem – volume: 48 start-page: 6517 year: 1988 ident: 149442_CR25 publication-title: Cancer Res – volume: 125 start-page: 107 year: 1990 ident: 149442_CR26 publication-title: Arch Surg doi: 10.1001/archsurg.1990.01410130113018 – volume: 4 start-page: 459 year: 1986 ident: 149442_CR12 publication-title: J Clin Oncol doi: 10.1200/JCO.1986.4.4.459 – volume: 10 start-page: 1284 year: 1992 ident: 149442_CR11 publication-title: J Clin Oncol doi: 10.1200/JCO.1992.10.8.1284 – volume: 30A start-page: 1663 year: 1995 ident: 149442_CR22 publication-title: Eur J Cancer – volume: 32 start-page: 559 year: 1984 ident: 149442_CR34 publication-title: Am J Clin Pathol doi: 10.1093/ajcp/82.5.559 – volume: 37 start-page: 185 year: 1996 ident: 149442_CR31 publication-title: Proceedings of the American Association for Cancer Research – volume: 1 start-page: 117 year: 1992 ident: 149442_CR9 publication-title: Breast doi: 10.1016/0960-9776(92)90212-K – volume: 5 start-page: 391 year: 1987 ident: 149442_CR14 publication-title: Adjuvant Ther Cancer – volume: 339 start-page: 1 year: 1992 ident: 149442_CR4 publication-title: Lancet – volume: 46 start-page: 844 year: 1980 ident: 149442_CR20 publication-title: Cancer doi: 10.1002/1097-0142(19800815)46:4<844::AID-CNCR2820460434>3.0.CO;2-5 – volume: 284 start-page: 869 year: 1982 ident: 149442_CR7 publication-title: Br Med J doi: 10.1136/bmj.284.6319.869-a – ident: 149442_CR24 – volume: 16 start-page: 323 year: 1980 ident: 149442_CR2 publication-title: Eur J Cancer doi: 10.1016/0014-2964(80)90348-5 – volume: 40 start-page: 1750 year: 1980 ident: 149442_CR17 publication-title: Cancer Res – volume: 1 start-page: 115 year: 1986 ident: 149442_CR13 publication-title: NCI Monographs – volume: 31 start-page: 13 year: 1983 ident: 149442_CR32 publication-title: Int J Cancer doi: 10.1002/ijc.2910310104 – volume: 67 start-page: 606 year: 1993 ident: 149442_CR21 publication-title: Br J Cancer doi: 10.1038/bjc.1993.111 – volume: 35 start-page: 292 year: 1977 ident: 149442_CR28 publication-title: Br J Cancer doi: 10.1038/bjc.1977.42 – volume: 47 start-page: 300 year: 1987 ident: 149442_CR16 publication-title: Cancer Res – volume: 30A start-page: 1218 year: 1994 ident: 149442_CR35 publication-title: Eur J Cancer doi: 10.1016/0959-8049(94)90161-9
SSID	ssj0009709
Score	1.811058
Snippet	To determine the effects of tamoxifen on the levels of hormone receptors and proliferation markers in the early phase of treatment and the relationship of the... Aim: To determine the effects of tamoxifen on the levels of hormone receptors and proliferation markers in the early phase of treatment and the relationship of...
SourceID	proquest pubmed pascalfrancis crossref
SourceType	Aggregation Database Index Database Enrichment Source
StartPage	11
SubjectTerms	Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Biomarkers, Tumor - analysis Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Cancer research Carcinoma - drug therapy Carcinoma - metabolism Chemotherapy Female Flow Cytometry Humans Immunohistochemistry Ki-67 Antigen - analysis Medical sciences Medical treatment Pharmacology. Drug treatments Receptors, Cell Surface - analysis Tamoxifen - therapeutic use
Title	Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
URI	https://www.ncbi.nlm.nih.gov/pubmed/9541185 https://www.proquest.com/docview/1027141471 https://www.proquest.com/docview/79784162
Volume	48
WOSCitedRecordID	wos000072340000002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1573-7217 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: M0R dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1573-7217 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: 7X7 dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1573-7217 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: BENPR dateStart: 19970101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1573-7217 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: 8C1 dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1573-7217 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: M2O dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1573-7217 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009709 issn: 0167-6806 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb5wwEB01m6qqVPU7CmmS-tBDL1QYG2yfqiRK1Eu2UdVKe0PGNspKCUuBVPkD-d8Zg9loK6WXXizAxgJmPH54xvMAPjkjM8dYGttc5jEvRRXLUqiYmVQZbTNBdTKQTYj5XC4W6iIsuHUhrHKyiYOhtivj18hxdKeCcoq29GvzO_asUd67Gig0tmDbZyrjM9g-Pp1f_HhIuyvGIA-f3TuXSf5Xch_EFgIRiFIp3ZiXXjS6w09UjdwWj4PPYRI6e_W_j_8aXgb4SY5GfXkDT1z9Fp6dBwf7O7gbdxt0ZFmTS4Szq9oRtImu8aQ8RNeWNJ7mp3Kj4pBrH93TDs17fb26xRo88kDUWVL6gPeeGK9YLQkZXMdeEHaSdorDu1w2xK8H45UhYNe9h19npz9PvsWBqSE2jKs-1hbtVKY1dSxDgJdXSmUIjFxipc2qRHK0DMqqjNPKVdQKTSupDecV8xRYVLMdmNX4RrtAJP5SsbRMnBSGGylKxcvclKWwzFqhdARfJjkVJqQx92waV8XgTk9ZcVRsCDaCz-sbmjGDx-NNDzYEv26f-pQ1UkWwPwm3CEO9Kx4kG8HHdTUOUu950bVb3XSFUIN7N41gZ1Sfdc_-myBk2vt3zx_g-bQXMqH7MOvbG3cAT82fftm1h7AlFmIoJZbyhB6GYYBn58lQpt_vASjJDx8
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LTtwwFL2itGorob4RoVC8aKVugmI7ie0FQogWgYBRF1Rilzq2I0YqmZCEPj6gv9Nv7HUeg6YS3bHoLpp4LMU59_o4Pr4H4K0zMnGcs9CmMg3jXBShzIUKuWHKaJsIqqPObEJMJvL8XH1agt_jWRgvqxxzYpeo7cz4b-QY3UzQmGIu3a2uQu8a5XdXRwuNHhbH7ud3XLI1O0cf8P2-Y-zg49n-YTi4CoSGx6oNtcWYSrSmjidIRtJCqQQncRdZaZMikjGiWFmVxLRwBbVC00JqE8cF93ZNVHPs9x7c95Xs_GJP7t9ISpToJSW-lngqo_SvUkLIZATyHaUYXZgFVyrd4AspeieN26luN-UdPP3fBusZPBnINdnro-E5LLnyBTw8HeQDL-FXf5aiIdOSXCBZn5WOYMZ3lbccIrq0pPImRoXrw4Jceu1S3TVv9eXsB97BK0-znSW5l_O3xPiwqclQn7bvBUk1qUeV4cW0Iv5rN_7SyZHdK_h8J4OwCsslPtEaEIkLRs7yyElhYiNFruI8NXkuLLdWKB3A9oiLzAxF2r1XyNesEwswnu1lC0AK4P38D1Vfn-T2ppsLQJu3Z74gj1QBbIxgyoZE1mQ3SApga34bU5DfV9Klm103mVDd5jULYLWH67xnPyZICNf_3fMWPDo8Oz3JTo4mx6_h8XjqM6IbsNzW124THphv7bSp33ThRuDLXUP2DxffZCk
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFL0qBVVIiHfVgZZ6ARKbQGwnsb1AqGoZURVGXYDUXXD8UEeimTRJeXwAP8XXcZ3HVINUdl2wixLHUpxzr0_i43sAnjsjU8c5i2wmsygphI9kIVTEDVNG21RQHXdmE2I2kycn6ngNfo97YYKscsyJXaK2CxP-kWN0M0ETirn0tR9kEccH07fVeRQcpMJK62in0UPkyP38jp9vzZvDA3zXLxibvvu0_z4aHAYiwxPVRtpifKVaU8dTJCaZVyrFCd3FVtrUxzJBRCur0oR656kVmnqpTZJ4HqybqObY7w24KTiiOOxS37-UlyjRy0tCXfFMxtlfZYWQ1QjkPkoxujIj3ql0gy_H964aV9Pebvqb3vufB-4-3B1IN9nro-QBrLnyIWx8HGQFj-BXv8eiIfOSnCKJX5SO4EzgqmBFRHRpSRXMjbzrw4WcBU1T3TVv9dniB17Bo0C_nSVFkPm3xIRwqslQt7bvBck2qUf14em8IuEvOJ7pZMruMXy-lkHYhPUSn2gLiMQPSc6K2ElhEiNFoZIiM0UhLLdWKD2BVyNGcjMUbw8eIl_zTkTAeL6Xr4BqAi-XN1R93ZKrm-6sgG7ZnoVCPVJNYHsEVj4kuCa_RNUEdpeXMTWF9SZdusVFkwvVLWqzCWz20F32HMYEieKTf_e8CxuI1PzD4ezoKdweN4PGdBvW2_rC7cAt862dN_WzLvIIfLluxP4BK8ps7g
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Changes+in+hormone+receptors+and+proliferation+markers+in+tamoxifen+treated+breast+cancer+patients+and+the+relationship+with+response&rft.jtitle=Breast+cancer+research+and+treatment&rft.au=MAKRIS%2C+A&rft.au=POWLES%2C+T.+J&rft.au=ALLRED%2C+D.+C&rft.au=ASHLEY%2C+S&rft.date=1998-03-01&rft.pub=Springer&rft.issn=0167-6806&rft.volume=48&rft.issue=1&rft.spage=11&rft.epage=20&rft_id=info:doi/10.1023%2FA%3A1005973529921&rft.externalDBID=n%2Fa&rft.externalDocID=2169389
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0167-6806&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0167-6806&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0167-6806&client=summon